These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24262190)

  • 1. Staged pathology in Parkinson's disease.
    Alafuzoff I; Parkkinen L
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S57-61. PubMed ID: 24262190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
    Wakabayashi K; Tanji K; Mori F; Takahashi H
    Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles.
    Meade RM; Fairlie DP; Mason JM
    Mol Neurodegener; 2019 Jul; 14(1):29. PubMed ID: 31331359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
    Roberts RF; Wade-Martins R; Alegre-Abarrategui J
    Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
    Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence in favor of Braak staging of Parkinson's disease.
    Dickson DW; Uchikado H; Fujishiro H; Tsuboi Y
    Mov Disord; 2010; 25 Suppl 1():S78-82. PubMed ID: 20187227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation and development of Lewy pathology: a critical update.
    Jellinger KA
    J Neurol; 2009 Aug; 256 Suppl 3():270-9. PubMed ID: 19711116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling Lewy pathology propagation in Parkinson's disease.
    Luk KC; Lee VM
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S85-7. PubMed ID: 24262196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
    Uchihara T; Giasson BI
    Acta Neuropathol; 2016 Jan; 131(1):49-73. PubMed ID: 26446103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
    Wang R; Sun H; Ren H; Wang G
    Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of α-synuclein is regulated in a neuronal cell type-dependent manner.
    Taguchi K; Watanabe Y; Tsujimura A; Tanaka M
    Anat Sci Int; 2019 Jan; 94(1):11-22. PubMed ID: 30362073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synapsin III is a key component of α-synuclein fibrils in Lewy bodies of PD brains.
    Longhena F; Faustini G; Varanita T; Zaltieri M; Porrini V; Tessari I; Poliani PL; Missale C; Borroni B; Padovani A; Bubacco L; Pizzi M; Spano P; Bellucci A
    Brain Pathol; 2018 Nov; 28(6):875-888. PubMed ID: 29330884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The mechanism of Lewy body formation in Parkinson's disease].
    Wakabayashi K; Takahashi H
    Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
    Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
    J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.
    Alegre-Abarrategui J; Ansorge O; Esiri M; Wade-Martins R
    Neuropathol Appl Neurobiol; 2008 Jun; 34(3):272-83. PubMed ID: 17971075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversy: is Parkinson's disease a single disease entity? Yes.
    Takahashi H; Wakabayashi K
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S31-7. PubMed ID: 15885626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration.
    Mahul-Mellier AL; Burtscher J; Maharjan N; Weerens L; Croisier M; Kuttler F; Leleu M; Knott GW; Lashuel HA
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4971-4982. PubMed ID: 32075919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.